FGAM
NBIX icon

Financial Gravity Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Financial Gravity Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3
Closed – – 1432
2019
Q2 		$0 Buy
+3
New +$246 ﹤0.01% 1521

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Financial Gravity Asset Management's NBIX Position: Q3 2019 in Review

Financial Gravity Asset Management sold out of Neurocrine Biosciences (NBIX) in Q3 2019, closing a stake of 3 shares.

Financial Gravity Asset Management first reported a position in NBIX in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 333 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Financial Gravity Asset Management reported no remaining Neurocrine Biosciences position as of Q3 2019 after selling out during the quarter.
  • Financial Gravity Asset Management sold 3 Neurocrine Biosciences shares in Q3 2019.
  • Financial Gravity Asset Management first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 1 quarter.
  • Financial Gravity Asset Management's Neurocrine Biosciences position peaked at $0 in Q2 2019.
  • 333 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Financial Gravity Asset Management's 13F filing for Q3 2019, filed 15 Oct 2019.